received regulatory approval for its generic equivalent to an infection-fighting
The Food and Drug Administration approval covers the antibacterial combination treatment consisting of ampicillin and sulbactam for injection, a generic equivalent to Pfizer's Unasyn. This marks the 10th approval Abraxis has received this year, the company says. The FDA is currently reviewing an additional 26 drug applications from the company.
Abraxis' hospital-based products division, Abraxis Pharmaceutical Products expects to begin marketing the treatment immediately. In 2005, sales of Pfizer's branded version of the drug were more than $10.4 million.